Gilead posts ZUMA-24 results for axi-cel in LBCL; denikitug trial still active, not recruitingNov 12Weekly roundup, 2 itemsaxicabtagene ciloleuceldenikitugUpdated
FDA approves nivolumab for adjuvant Stage IIB/C melanoma treatmentNov 10Regulatory decisionBristol Myers Squibbnivolumab
FDA accelerated approval covers Padcev plus Keytruda in urothelial carcinomaNov 9Regulatory decisionenfortumab vedotinMerck & Co., Inc.
FDA approves daraxonrasib as Elicio preps Phase 1 trial combining it with camupepimutNov 6Regulatory decisiondaraxonrasibElicio TherapeuticsUpdated
BMS registers observational LUNIS study of Reblozyl in lower-risk MDS patients in GermanyNov 6Weekly roundup, 3 itemsBristol Myers Squibbluspatercept
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Johns Hopkins-sponsored HCC trial of Nivolumab plus Relatlimab posts results, now not recruitingOct 29Weekly roundup, 2 itemsBristol Myers Squibbnavlimetostat
Wave Life Sciences details Q3 2026 progress on WVE-006, WVE-007, WVE-008 pipelineOct 28Quarterly updateBristol Myers SquibbEli LillyUpdated
Replimune reports early TUDRIQEV launch progress, $307.8 million cash as of Sept. 30, 2026Oct 28Quarterly updateReplimune, Inc.
BMS: Reblozyl label supplement approved; GLORY CAR-T trial and BMS-986485 Phase 1 postedOct 22Weekly roundup, 4 itemsBristol Myers Squibbliso-celUpdated
Arcus files preliminary prospectus supplement, cites new casdatifan ccRCC dataOct 21Clinical readoutArcus Biosciences, Inc.casdatifanUpdated
BeOne Medicines registers Phase 1 trial of BG-T0050 in DLBCL and other B-cell cancersOct 21Weekly roundup, 5 itemsazacitidineBeiGene
BMS posts RELATIVITY-106 liver cancer results; files two new Phase 1/2 trialsOct 16Weekly roundup, 4 itemsBioNTech SEBristol Myers SquibbUpdated
AstraZeneca completes Phase 1 laroprovstat/ezetimibe bioavailability study in healthy adultsOct 2Weekly roundup, 6 itemsacalabrutinibanifrolumab-fnia
BMS registers Phase 1 CAR T cell trial in kidney cancer; adds mavacamten real-world studyOct 1Weekly roundup, 5 itemsBristol Myers SquibbgolcadomideUpdated
Mirati's SAPPHIRE trial in NSCLC terminated, results posted on ClinicalTrials.govSep 30Trial updateBristol Myers Squibbnivolumab
BMS trials update: CheckMate-67T posts results; two studies added for irAE care and lung screeningSep 25Weekly roundup, 5 itemsBristol Myers Squibbclarithromycin
BMS logs three FDA label approvals and posts results for melanoma combo trialSep 2Weekly roundup, 5 itemsadagrasibBristol Myers Squibb
BMS registers new deucravacitinib continuation study; prior week's trial results still standAug 27Weekly roundup, 5 itemsBristol Myers Squibbdeucravacitinib
NovaBridge reports H1 2026 results, targets year-end Phase 3 start for givastomigAug 20Quarterly updateNovaBridge Biosciences
Replimune's TUDRIQEV wins FDA accelerated approval, launch set within 60 daysAug 14Quarterly updateReplimune, Inc.
BMS posts JAKARTA Phase 3 results, updates Opdivo label, registers golcadomide renal studyAug 13Weekly roundup, 4 itemsBristol Myers Squibbgolcadomide
Perspective Therapeutics reports 2Q 2026 results, advances toward VMT-α-NET Phase 3Aug 10Clinical readoutPerspective Therapeutics
Replimune's $150 million offering formalized in prospectus supplement filed with SECAug 10FinancingReplimune, Inc.
FDA grants accelerated approval to Replimune's TUDRIQEV plus nivolumab for melanomaAug 6Regulatory decisionnivolumabReplimune, Inc.
Xencor reports Q2 2026 results, sets ESMO date for XmAb819 kidney cancer dataAug 5Quarterly updateXencor, Inc.XMAB819
Arcus Biosciences advances casdatifan combinations, reports $775M cash at midyear 2026Aug 5Quarterly updateArcus Biosciences, Inc.AstraZeneca
FDA advisory committee backs RP1 efficacy data in advanced melanoma, 10-3Jul 30Regulatory milestoneReplimune, Inc.
Bicycle Therapeutics reports Q2 2026 pipeline progress, cash into 2030Jul 30Quarterly updateBicycle Therapeutics Plc
Corcept raises 2026 revenue guidance to $1.1-$1.2 billion after Lifyorli launch quarterJul 29Quarterly updateCorcept Therapeuticsmifepristone
Scancell to merge with Neuphoria and list on Nasdaq, plans up to $89 million financingJul 23PartnershipNeuphoria Therapeutics Inc.
BMS trials post results across lung cancer, sarcoma, myelofibrosis; new stroke study opensJul 17Weekly roundup, 5 itemsBristol Myers Squibblisocabtagene maraleucel
BMS posts PRIME-HCC results; adds SOTYKTU label update, Phase 3 lung trialJul 2Weekly roundup, 7 itemsBristol Myers Squibbcisplatin
Replimune's RP1 BLA resubmission accepted by FDA; adcomm expected late JulyJun 29Quarterly updateReplimune, Inc.